Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥2,610 JPY
Change Today -57.00 / -2.14%
Volume 283.0K
As of 2:00 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

kyorin holdings inc (4569) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/12/15 - ¥3,040
52 Week Low
06/10/14 - ¥1,931
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KYORIN HOLDINGS INC (4569)

Related News

No related news articles were found.

kyorin holdings inc (4569) Related Businessweek News

No Related Businessweek News Found

kyorin holdings inc (4569) Details

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical, generic, over-the-counter drugs, and others in Japan and internationally. The company operates in two segments, Pharmaceutical Business and Consumer Healthcare (Skincare) Business. Its products primarily include Flutiform, a drug for the treatment of asthma; Uritos, which is a therapeutic agent for overactive bladder; Kipres for the treatment of bronchial asthma and allergic rhinitis; Pentasa for the treatment of ulcerative colitis and Crohn’s disease; and Mucodyne, a mucoregulan drug. The company also offers Milton, a baby bottle disinfectant; Rubysta, a disinfectant cleaner; skincare and cosmetic products based on nanocapsule technology, a pharmaceutical formulation concept; and prescription medicines and quasi-drugs, diagnostics, and industrial chemicals. In addition, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies’ technologies and collection of information concerning clinical trials. Further, the company’s pipeline products include KRP-AB1102 and KRP-AB1102F for the treatment of chronic obstructive pulmonary disease that are under Phase III clinical development; KRP-AM1977X for the treatment of infectious diseases that is under Phase II clinical development; and KRP-114V and KRP-EPA605 for overactive bladder. Additionally, it pipeline products comprise KRP-209 for Tinnitus; KRP-203 for transplantation, autoimmune diseases, and IBD; KRP-AM1977X, an oral antibacterial agent; and KRP-AM1977Y, an injection. The company’s other pipeline products include Ad-SGE-REIC formulation, a gene-therapy product; and Dimethyl sulfoxide for the treatment of interstitial cystitis. KYORIN Holdings, Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Founded in 1923

kyorin holdings inc (4569) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyorin holdings inc (4569) Key Developments

Kyorin Holdings, Inc. Announces Consolidated Earnings Results for the Full Year Ended March 31, 2015; Provides Earnings Forecast for the Six Months and Full Year of Fiscal 2016; Announces Dividend for the Year End of Fiscal Year 2015, Payable on June 9, 2015; Provides Dividend Guidance for the Second Quarter and Year End of Fiscal Year 2016

KYORIN Holdings, Inc. announced consolidated earnings results for the full year ended March 31, 2015. For the year, the company reported net sales of JPY 113,121 million compared with JPY 111,400 million for the same period a year ago. Operating income was JPY 14,737 million compared with JPY 17,607 million for the same period a year ago. Ordinary income was JPY 15,490 million compared with JPY 18,281 million for the same period a year ago. Net income was JPY 12,064 million or JPY 161.63 per share compared with JPY 12,025 million or JPY 160.95 per share for the same period a year ago. Return on equity was 8.4% compared with 9.0% for the same period a year ago. Cash flows from operating activities was JPY 6,391 million compared with JPY 19,293 million for the same period a year ago. The company provided earnings guidance for the first half of fiscal 2016 and for the full year ending March 31, 2016. For the first half, the company expects to report net sales of JPY 54,400 million, operating income of JPY 3,800 million, ordinary income of JPY 4,000 million and net income of JPY 2,600 million or JPY 35.16 per share. For the full year ending March 31, 2016, the company expects to report net sales of JPY 120,200 million, operating income of JPY 16,000 million, ordinary income of JPY 16,300 million and net income of JPY 11,500 million or JPY 155.51 per share. The company announced a year end dividend of JPY 32.00 per share, payable on June 9, 2015. The company provided dividend guidance for the second quarter and for the fiscal year ending March 31, 2016. For the second quarter, the company plans to pay a dividend of JPY 20.00 per share and a final dividend of JPY 32.00 per share.

KYORIN Holdings, Inc., 2015 Earnings Call, May 14, 2015

KYORIN Holdings, Inc., 2015 Earnings Call, May 14, 2015

KYORIN Holdings, Inc. to Report Fiscal Year 2015 Results on May 13, 2015

KYORIN Holdings, Inc. announced that they will report fiscal year 2015 results on May 13, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4569:JP ¥2,610.00 JPY -57.00

4569 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4569.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4569 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYORIN HOLDINGS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at